Retrospective Study

Trends and outcomes of liver transplantation among older recipients in the United States

Kenji Okumura, Joon Sub Lee, Abhay Dhand, Hiroshi Sogawa, Gregory Veillette, Devon John, Ryosuke Misawa, Roxana Bodin, David C Wolf, Thomas Diflo, Seigo Nishida

Abstract

BACKGROUND

The average age of recipients and donors of liver transplantation (LT) is increasing. Although there has been a change in the indications for LT over the years, data regarding the trends and outcomes of LT in the older population is limited.

AIM

To assess the clinical characteristics, age-related trends, and outcomes of LT among the older population in the United States.

METHODS

We analyzed data from the United Network for Organ Sharing database between 1987-2019. The sample was split into younger group (18-64 years old) and older group (≥ 65 years old).

RESULTS

Between 1987-2019, 155758 LT were performed in the United States. During this period there was a rise in median age of the recipients and percentage of LT recipients who were older than 65 years increased (P < 0.05) with the highest incidence of LT among older population seen in 2019 (1920, 23%). Common primary etiologies of liver disease leading to LT in older patients when compared to the younger group, were non-alcoholic steatohepatitis (16.4% vs 5.9%), hepatocellular carcinoma (14.9% vs 6.9%), acute liver failure (2.5% vs 5.2%), hepatitis C cirrhosis (HCV) (19.2% vs 25.6%) and acute alcoholic hepatitis (0.13% vs 0.35%). In older recipient group female sex and Asian race were higher, while model for end-stage liver disease (MELD) score and rates of preoperative mechanical
ventilation were lower ($P < 0.01$). Median age of donor, female sex, body mass index (BMI), donor HCV positive status, and donor risk index (DRI) were significantly higher in older group ($P < 0.01$). In univariable analysis, there was no difference in post-transplant length of hospitalization, one-year, three-year and five-year graft survivals between the two groups. In multivariable Cox-Hazard regression analysis, older group had an increased risk of graft failure during the five-year post-transplant period (hazard ratio: 1.27, $P < 0.001$). Other risk factors for graft failure among recipients were male sex, African American race, re-transplantation, presence of diabetes, mechanical ventilation at the time of LT, higher MELD score, presence of portal vein thrombosis, HCV positive status, and higher DRI.

**CONCLUSION**

While there is a higher risk of graft failure in older recipient population, age alone should not be a contraindication for LT. Careful selection of donors and recipients along with optimal management of risk factors during the postoperative period are necessary to maximize the transplant outcomes in this population.

**Key Words:** Liver transplant; Elderly; Outcomes; Hepatocellular carcinoma; Nonalcohol steatohepatitis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Liver transplantation (LT) among older patients is becoming more acceptable in the United States. The overall outcomes of LT for patients ≥ 65 years are comparable to younger recipients. While there is a higher risk of graft failure in older recipient population, age alone should not be a contraindication for LT. Careful selection of donors and recipients along with optimal management of risk factors during the postoperative period are necessary to maximize the transplant outcomes in this population.

Citation: Okumura K, Lee JS, Dhand A, Sogawa H, Veillette G, John D, Misawa R, Bodin R, Wolf DC, Diflo T, Nishida S. Trends and outcomes of liver transplantation among older recipients in the United States. *World J Transplant* 2022; 12(8): 259-267

URL: https://www.wjgnet.com/2220-3230/full/v12/i8/259.htm

DOI: https://dx.doi.org/10.5500/wjt.v12.i8.259

**INTRODUCTION**

Liver disease is one of the most frequent causes of death in the United States[1,2]. Liver transplantation (LT) is the most effective life-saving treatment for patients with end-stage liver disease and liver failure. Over the past few decades, the number of LT in the United States has increased and outcomes of these transplants have significantly improved[3,4]. According to the United Network for Organ Sharing (UNOS) database, in 1987 there were 1713 LT performed in the United States. Since then, there has been a more than five-fold increase in the number of LTs, with 8906 cases performed in 2020. As the general population becomes older, the average ages of LT recipients and donors have increased as well[5]. Over the past three decades, the characteristic of donors and recipients of LT for end-stage liver disease has changed considerably[3,6-8]. Our goal was to assess trends in the etiology of underlying liver disease, and outcomes of LT among older population in the United States.

**MATERIALS AND METHODS**

**Patients and selection criteria**

We evaluated all patients 18 years or older who underwent LT in the United States from January 1, 1987 to December 31, 2019 in the UNOS database. Patients without a documented primary diagnosis were excluded from the analyses. This study was approved by our Institutional Review Board.

**Patient characteristics and outcome variables**

All data were collected from the UNOS registry. Demographic information, such as listing diagnosis, age, gender and race, along with time on waiting list prior to transplant were included in the analyses. Additional variables, such as model for end-stage liver disease (MELD) score at listing on the waitlist and at the time of transplant, body mass index (BMI), pre-transplant diabetes mellitus (DM), hepatitis C
virus (HCV) status, dialysis prior to transplant, previous abdominal surgery, spontaneous bacterial peritonitis, trans-jugular intrahepatic portosystemic shunt, portal vein thrombosis, mechanical ventilation status and donor risk index (DRI) \[9\], were included as well. The study groups were defined as older (≥ 65 years old) and younger (18-64 years old).

**Statistics**

Statistical analyses were performed using IBM SPSS Statistics 26.0 (IBM Corp., Armonk, NY, United States). Non-parametric analyses were used to compare continuous variables (Mann-Whitney U test) and categorical variables (Chi-square test or Fisher’s exact test). The overall survival and graft survival were calculated from the date of transplant to the date of the event using the Kaplan-Meier method. Survival curves were compared by using the log-rank test. Cox-Hazard regression analyses were applied to assess the association between multiple covariate factors and survival rates between two groups. Results were presented as hazard ratios and reported with 95% confidence intervals with \( P \) values. \( P < 0.01 \) was taken as statistically significant.

**RESULTS**

**Recipient characteristics**

Of the 155758 individuals who received a LT during the study period, 20000 were in older group (≥ 65 years old) and 135758 patients were in younger group (18-64 years old). The trends of LT in older patients are shown in Figure 1A. The overall number and percentage of LT in older group increased over the years, and the percentage of older recipients became > 20% after 2016. The trends of indications for LT in the older population is shown in Figure 1B. HCV cirrhosis was the most common indication for LT from 1994 to 2005. The number of patients requiring LT due to hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH) also gradually increased during the study period. HCC became the most common indication for LT in older group from 2006 to 2018. In 2019, NASH became the most common indication for LT in older group. Table 1 presents the characteristics of recipients who underwent LT during the study period. The median age of recipients was 52 years in the younger group and 67 years in the older group. Recipients in older group were more likely to be female, White, and Asian compared to those in younger group (\( P < 0.001 \)). Recipients in younger group were more likely to be HCV positive and have portal vein thrombosis, while recipients in older group were more likely to have pre-transplant DM. For primary etiology of liver disease, younger group was more likely to have alcohol-related liver disease (ALD), HCV cirrhosis and acute liver failure, while older group was more likely to have NASH and HCC. Additionally, the younger group was more likely to be on mechanical ventilation at the time of LT and have a prior history of LT.

**Donor characteristics**

The median donor age was higher in the older group (43 years vs 38 years, \( P < 0.001 \)) (Table 2). The donors of older recipients were more likely to be female, have a higher BMI, and have a higher DRI.
Table 1 Baseline characteristics of the study population comparing age young group (age 18-64) vs older group (age ≥ 65 years)

|                             | Young group, age 18-64 (n = 135758) | Older group, age ≥ 65 (n = 20000) | P value |
|-----------------------------|--------------------------------------|-----------------------------------|---------|
| Age (IQR)                   | 52 (45-58)                           | 67 (66-69)                        | < 0.001 |
| Female, n (%)               | 47934 (35.3)                         | 7612 (38.1)                       | < 0.001 |
| Race, %                     |                                      |                                   | < 0.001 |
| White                       | 73.5                                 | 75.5                              |         |
| Black                       | 8.9                                  | 6.0                               |         |
| Hispanic/Latino             | 12.5                                 | 12.1                              |         |
| Asian                       | 3.8                                  | 5.4                               |         |
| Others                      | 1.3                                  | 0.9                               |         |
| BMI (IQR)                   | 27.4 (24.0-31.7)                     | 27.7 (24.5-31.5)                  | 0.571   |
| HCV, %                      | 44876 (33.1)                         | 5226 (26.2)                       | < 0.001 |
| Diabetes, n (%)             | 226584 (22.3)                        | 6784 (35.7)                       | < 0.001 |
| L1-MELD                     | 18 (12-26)                           | 15 (10-22)                        | < 0.001 |
| R2-MELD                     | 21 (14-30)                           | 18 (12-26)                        | < 0.001 |
| Primary disease, %          |                                      |                                   |         |
| Alcohol cirrhosis           | 22.3                                 | 15.3                              | < 0.001 |
| HCV cirrhosis               | 25.2                                 | 19.0                              | < 0.001 |
| NASH                        | 5.9                                  | 16.4                              | < 0.001 |
| HCC                         | 6.9                                  | 14.9                              | < 0.001 |
| Acute liver failure         | 5.2                                  | 2.5                               | < 0.001 |
| Acute alcoholic hepatitis   | 0.35                                 | 0.13                              | < 0.001 |
| Previous surgery, n (%)     | 48407 (35.7)                         | 8899 (44.5)                       | < 0.001 |
| SBP, n (%)                  | 9147 (6.7)                           | 1084 (5.4)                        | < 0.001 |
| TIPSS, n (%)                | 7231 (5.3)                           | 1187 (5.9)                        | 0.001   |
| Portal vein thrombosis, n (%)| 4875 (3.6)                         | 1162 (5.8)                        | < 0.001 |
| Mechanical ventilation, n (%)| 10464 (7.6)                       | 888 (4.3)                         | < 0.001 |
| Dialysis, n (%)             | 14284 (10.5)                         | 2059 (10.3)                       | 0.167   |
| Wait days, d (IQR)          | 82 (16-263)                          | 118 (27-310)                      | < 0.001 |
| Re-transplant, n (%)        | 10125 (7.5)                          | 727 (6.6)                         | < 0.001 |

1Listing.
2Most recent.

IQR: Interquartile; BMI: Body mass index; HCV: Hepatitis C virus; NASH: Non-alcohol steatohepatitis; HCC: Hepatocellular carcinoma; SBP: Spontaneous bacterial peritonitis; TIPSS: Trans-jugular intrahepatic portosystemic shunt; MELD: Model for end-stage liver disease.

Outcomes

Kaplan-Meier survival analysis showed no significant differences in the 1, 3, and 5-year graft survival between the two groups, but overall survival was lower in the older group (Table 2). Multivariable Cox-Hazard regression analyses were performed to identify the factors associated with five-year graft failure (Table 3). Factors associated with five-year graft failure were recipient age ≥ 65 years, pre-LT DM, re-LT, male gender, African American race, ventilation at the time of LT, high MELD score (per 10), recipient portal vein thrombosis at time of LT, recipient HCV positive status, and high DRI. Transplants performed during the latter part of the study had a protective effect on five-year graft survival. In a subgroup analysis of older recipients, male gender, pre-LT DM, previous LT, ventilation at the time of LT, higher MELD score (per 10), portal vein thrombosis, HCV positive status, and higher DRI were associated with worse five-year graft survival (Table 4 and Figure 2).
### Table 2 Donor characteristics and post-transplant outcomes

|                              | Young, age 18-64 (n = 135758) | Older, age ≥ 65 (n = 20000) | P value |
|------------------------------|--------------------------------|-----------------------------|---------|
| Donor age (IQR)              | 38 (24-52)                     | 43 (28-56)                  | < 0.001 |
| Donor female, n (%)          | 53967 (39.8)                   | 8434 (42.2)                 | < 0.001 |
| Donor race, %                |                                |                             | < 0.001 |
| White                        | 70.3                           | 68.2                        |         |
| Black                        | 14.6                           | 15.5                        |         |
| Hispanic/Latino              | 11.6                           | 12.4                        |         |
| Asian                        | 2.1                            | 2.4                         |         |
| Others                       | 1.4                            | 1.6                         |         |
| Donor BMI (IQR)              | 25.6 (22.5-29.5)               | 26.2 (23.0-30.3)            | < 0.001 |
| Donor HCV, n (%)             | 4912 (3.6)                     | 907 (4.5)                   | < 0.001 |
| Cold ischemia time, h (IQR)  | 6.9 (5.0-9.0)                  | 6.1 (4.8-8.0)               | < 0.001 |
| Donor risk index (IQR)       | 1.53 (1.35-1.81)               | 1.61 (1.38-1.94)            | < 0.001 |
| Outcomes                     |                                |                             |         |
| LOS, d (IQR)                 | 11 (7-20)                      | 10 (7-19)                   | 0.261   |
| Graft survival rate, (%)     |                                |                             |         |
| 1 yr                         | 84.0                           | 84.1                        | 0.416   |
| 3 yr                         | 77.0                           | 77.1                        | 0.206   |
| 5 yr                         | 72.6                           | 72.9                        | 0.010   |
| Overall survival rate        |                                |                             |         |
| 1 yr                         | 88.6                           | 86.5                        | < 0.001 |
| 3 yr                         | 82.5                           | 79.5                        | < 0.001 |
| 5 yr                         | 78.3                           | 75.1                        | < 0.001 |

IQR: Interquartile range; BMI: Body mass index; LOS: Post-transplant length of hospital stay; HCV: Hepatitis C virus.

### DISCUSSION

This study utilized the UNOS database to analyze the trends and outcomes of LT in older patients. The results show an overall increase in total number of LT in older population over time, as well as significant changes in the trends of the primary etiology of LT. In older recipients, univariable analysis showed comparable graft survival, while multivariable analysis showed a lower graft and overall survival. But, these inferior results in older population may otherwise be considered acceptable.

The improvements in surgical techniques and perioperative care have allowed for a gradual increase LT for older recipients[4,5]. The presence of chronic liver diseases like HCV, NASH, and associated HCC in the older patients may have led to an increase in end-stage liver disease, requiring LT[10]. The recent improvements in HCV treatment has likely played a significant role in the change in primary indication for LT. Overall, the most current common indication for LT is ALD across all ages, however, our study shows that NASH and HCC are the leading causes of LT, with no increase in ALD in the older population. Durand et al[4] have shown that in LT, older recipients have a lower chance of liver allograft rejection. Additionally, they reported that patients with non-autoimmune conditions, such as NASH and alcoholic cirrhosis, do not require higher maintenance immunosuppression compared to other LT recipients[4]. Historically a subset of patients with positive HCV serostatus had a recurrence of HCV after LT[11]. HCV recurrence post-LT and subsequent chronic HCV infection would lead to drastic consequences, as chronic inflammation, fibrosis, and ultimately graft failure[12]. However, with the development of Direct-Acting Antivirals (DAA), there has been a major shift in the primary etiology of LT with the overall decrease in need of LT for chronic HCV infection[6]. Our analyses further showed that recipient HCV status was one of the risk factors for graft failure. This was likely before the availability of DAA, which has now become the therapy of choice for effectively curing HCV infection[13]. The recent studies show that DAA achieves high sustained virologic response in LT recipients and the elimination of HCV will prevent chronic inflammation, thereby avoiding the risk of compromising...
Table 3 Multivariable cox regression for five-year graft survival

| Variables                  | B (SE)      | Hazard ratio (95%CI) | P value |
|----------------------------|-------------|----------------------|---------|
| Year of transplant         | -0.04 (0.002) | 0.958 (0.955-0.961) | < 0.001 |
| Age ≥ 65                   | 0.24 (0.02)  | 1.27 (1.22-1.32)    | < 0.001 |
| Male                       | 0.10 (0.02)  | 1.11 (1.08-1.14)    | < 0.001 |
| BMI (per 10)               | -0.05 (0.01) | 0.95 (0.93-0.98)    | 0.001   |
| Race                       |             |                      |         |
| Caucasian                  | Ref         | 1.0 (Ref)            |         |
| African American           | 0.23 (0.02)  | 1.26 (1.21-1.31)    | < 0.001 |
| Hispanic                   | -0.11 (0.02) | 0.90 (0.86-0.94)    | < 0.001 |
| Asian                      | -0.21 (0.04) | 0.81 (0.75-0.87)    | < 0.001 |
| Pre-LT diabetes            | 0.20 (0.02)  | 1.22 (1.18-1.26)    | < 0.001 |
| Ventilation                | 0.51 (0.03)  | 1.67 (1.59-1.76)    | < 0.001 |
| Pre-LT dialysis            | 0.20 (0.02)  | 1.23 (1.17-1.28)    | < 0.001 |
| Retransplant               | 0.44 (0.03)  | 1.55 (1.47-1.63)    | < 0.001 |
| PVT                        | 0.21 (0.03)  | 1.23 (1.16-1.31)    | < 0.001 |
| R1-MELD (per 10)           | 0.04 (0.01)  | 1.05 (1.03-1.06)    | < 0.001 |
| HCV recipient              | 0.28 (0.01)  | 1.33 (1.29-1.36)    | < 0.001 |
| Donor race                 |             |                      | < 0.001 |
| Caucasian                  | Ref         | 1.0 (Ref)            |         |
| African American           | 0.06 (0.02)  | 1.06 (1.02-1.10)    | 0.001   |
| Hispanic                   | 0.10 (0.02)  | 1.11 (1.06-1.16)    | < 0.001 |
| Asian                      | 0.19 (0.04)  | 1.21 (1.11-1.31)    | < 0.001 |
| Donor risk index           | 0.34 (0.03)  | 1.41 (1.34-1.48)    | < 0.001 |
| Cold ischemia time         | 0.014 (0.002) | 1.014 (1.010-1.019) | < 0.001 |

1Most recent.

BMI: Body mass index; LT: Liver transplantation; PVT: Portal vein thrombosis; CI: Confidence interval; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease.

As in our study, pre-transplant DM has previously been shown to be associated with worse outcomes in LT[16]. Diabetes is a metabolic disease and is associated with increased morbidity after LT[17,18]. The prevalence of NASH in patients with type 2 diabetes is more than 2-fold higher compared to the general population[19]. Poorly controlled diabetes is also strongly associated with NASH and accelerates the progression of liver disease. NASH and diabetes also increase cardiovascular risks[20]. These cumulative risk factors should be carefully evaluated for the post-transplant management of older patients.

In patients with cirrhosis, the requirement of mechanical ventilation at time of transplant is associated with an increased risk of post-operative mortality[21]. In our study, older patients were less likely to be intubated at the time of transplant, this would be related to cautious recipient selection. The patients' requirements for dialysis and comorbidities of kidney dysfunction also had a significant impact on the outcomes of LT[22], which is further correlated with a higher MELD score. In our study, older patients had a lower MELD score and need for dialysis at the time of transplant, which might reflect the individual transplant center selection criteria for older recipients.

There were several limitations to this study. First, primary diagnosis at the time of listing for LT was used, but this diagnosis may not be accurate. If an alternative diagnosis is found post-transplant, these changes may not be recorded in the UNOS database. Secondly, we have evaluated only the patients who received LT, which means that older patients with comorbidities and/or severe clinical conditions who were not considered to be a candidate for LT, added to the selection bias in this study. Finally, long-term data regarding the graft and overall survival among older recipients is limited.
Table 4 Multivariable cox regression for five-year graft survival in older group

| Variables                  | B (SE)     | Hazard ratio (95%CI)      | P value |
|----------------------------|------------|--------------------------|---------|
| Year of transplant         | -0.05 (0.004) | 0.954 (0.947-0.961)      | < 0.001|
| Male                       | 0.19 (0.04)  | 1.21 (1.12-1.30)         | < 0.001|
| Re-transplant              | 0.41 (0.08)  | 1.50 (1.28-1.76)         | < 0.001|
| Pre-LT diabetes            | 0.17 (0.04)  | 1.18 (1.10-1.27)         | < 0.001|
| Ventilation                | 0.42 (0.08)  | 1.52 (1.30-1.76)         | < 0.001|
| Portal vein thrombosis     | 0.18 (0.07)  | 1.20 (1.05-1.36)         | 0.006   |
| MELD (per 10)              | 0.13 (0.02)  | 1.14 (1.10-1.18)         | < 0.001|
| HCV Recipient              | 0.21 (0.04)  | 1.23 (1.15-1.33)         | < 0.001|
| Donor age (per 10)         | 0.03 (0.01)  | 1.03 (1.002-1.054)       | 0.032   |
| Donor risk index           | 0.25 (0.06)  | 1.29 (1.15-1.44)         | < 0.001|
| Cold ischemia time         | 0.017 (0.006) | 1.02 (1.01-1.03)       | 0.003   |

LT: Liver transplantation; MELD: Model for end-stage liver disease; HCV: Hepatitis C virus; CI: Confidence interval.

**CONCLUSION**

The number of LT in older recipients has significantly increased over time along with the change in indication of LT. Older age alone should not be a contraindication for LT, however, careful evaluation processes and postoperative care are necessary to improve the transplant outcomes.

**ARTICLE HIGHLIGHTS**

**Research background**

The average age of liver transplant and the number of liver transplant in the older recipients is increasing.
Okumura K et al. LT for older recipients

**Research motivation**
We wanted to investigate the outcomes of expansion of criteria of liver transplantation (LT) with increasing inclusion of older recipients and donors. We also wanted to identify any potentially modifiable risk factors that may be associated lower with graft or patient survival.

**Research objectives**
We compared one, three- and five-year graft and patient survival between two groups of liver transplant recipients: Younger group (18-64 years old) and older group (≥ 65 years old) between the period of 1987-2019 in the United States.

**Research methods**
We analyzed data from the United Network for Organ Sharing database between 1987-2019. The sample was split into younger group (18-64 years old) and older group (≥ 65 years old).

**Research results**
The number of LT for older patients was highest in 2019 (1920). In the older group, the percentage of non-alcoholic steatohepatitis and hepatocellular carcinoma as the primary etiology for LT was higher than younger group compared to the older group (16.4% vs 5.9%; 14.9% vs 6.9%). On univariable analysis, there was no difference in post-transplant length of hospitalization, one-year and five-year overall survivals between the two groups. On multivariable Cox-Hazard regression analysis for graft survival, older group (hazard ratio: 1.27, \( P < 0.001 \)) had higher risk of graft failure which was associated with male gender, pre-transplant diabetes, previous history of LT, ventilation at the time of LT, high model for end-stage liver disease score, recipient portal vein thrombosis, hepatitis C virus positive status, and higher donor risk index.

**Research conclusions**
Older age alone should not be considered to be a contraindication for LT.

**Research perspectives**
Careful evaluation process and postoperative care are necessary to improve transplant outcomes.

**ACKNOWLEDGEMENTS**
The data reported here have been supplied by the UNOS as the contractor for the OPTN. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the OPTN or the United States Government.

**FOOTNOTES**

**Author contributions:** Okumura K, Nishida S contributed to the study design, data analysis, data interpretation, and writing manuscript; Lee JS, Dhand A, Sogawa H, Veillette G, John D, Misawa R, Bodin R, Wolf DC, and Diflo T revised manuscript and critical revisions; and all authors approved the final version of the manuscript.

**Institutional review board statement:** All study methods were approved by our Institutional Review Board.

**Informed consent statement:** The informed consent statement was waived.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** Data is available on request from the authors.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** United States

**ORCID number:** Kenji Okumura 0000-0002-7751-2624; Joon Sub Lee 0000-0003-1151-1343; Abhay Dhand 0000-0003-3527-1938; Hiroshi Sogawa 0000-0003-3724-9005; Gregory Veillette 0000-0001-8635-0578; Devon John 0000-0002-2192-4929; Ryosuke Misawa 0000-0001-8429-3135; Roxana Bodin 0000-0002-8679-239X; David C Wolf 0000-0001-6819-9675; Thomas Diflo 0000-0002-4059-2309; Seigo Nishida 0000-0002-1504-3551.
Corresponding Author's Membership in Professional Societies: American Association for the Study of Liver Diseases.

S-Editor: Wang JJ
L-Editor: A
P-Editor: Wang JJ

REFERENCES

1 Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018; 155: 1154-1163.e3 [PMID: 30009816 DOI: 10.1053.j.gastro.2018.07.008]

2 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019; 70: 151-171 [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014]

3 Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Norseen SM, Foutz J, Booker SE, Cafarella M, Snyder JJ, Israni AK, Kasikishe BK. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant 2021; 21 Suppl 2: 208-315 [PMID: 33595192 DOI: 10.1111/ajt.16494]

4 Durand F, Levitsky J, Cauhy F, Gilgenkranz H, Sobrane O, Francoz C. Age and liver transplantation. J Hepatol 2019; 70: 745-758 [PMID: 30576701 DOI: 10.1016/j.jhep.2018.12.009]

5 Su F, Yu L, Berry K, Liu IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology 2016; 150: 441-53.e6; quiz e16 [PMID: 26252262 DOI: 10.1053/j.gastro.2015.10.043]

6 Puiuichi M, Hashini D, Haber PK, Dinani A, Schiano TD, Asgharpoor A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dietrich D, Boffeta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020; 20: 220-230 [PMID: 31437349 DOI: 10.1111/ajt.15576]

7 Mathurin P, Lucey MR. Liver transplantation in patients with alcohol-related liver disease: current status and future directions. Lancet Gastroenterol Hepatol 2020; 5: 507-514 [PMID: 32277903 DOI: 10.1016/S2468-1258(19)30451-0]

8 Brancaccio G, Vitale A, Signoriello G, Gaeta GB, Cillo U. Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infect Dis (Lond) 2020; 52: 557-562 [PMID: 32401092 DOI: 10.1080/23744235.2020.1763453]

9 Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, Merion RM. Characteristics associated with liver graft failure: the concept of a donor risk factor. Am J Transplant 2006; 6: 783-790 [DOI: 10.1111/j.1600-6143.2006.01242.x]

10 Shirazi F, Wang J, Wong RJ. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. Clin Exp Hepatol 2019; 10: 30-36 [PMID: 32025164 DOI: 10.1016/j.jche.2019.06.007]

11 Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatobiliary Pancreat Surg 2005; 12: 448-456 [PMID: 15763325 DOI: 10.1016/j.jhepb.2005.01.011]

12 Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041 [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014]

13 Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol 2018; 24: 5297-5311 [PMID: 30508575 DOI: 10.3748/wjg.v24.i47.5297]

14 Cotter TG, Paul S, Sandakci B, Court T, Bodzin AS, Little EC, Sundaram V, Charlton M. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Antiviral Era. Liver Transpl 2019; 25: 598-609 [PMID: 30716208 DOI: 10.1002/lt.25424]

15 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant 2019; 19: 1380-1387 [PMID: 30378723 DOI: 10.1111/ajt.15162]

16 Zhang Q, Deng YL, Liu C, Huang LH, Shang L, Chen XG, Wang LT, Du JZ, Wang Y, Wang PX, Zhang H, Shen ZY. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2016; 22: 9571-9585 [PMID: 27920478 DOI: 10.3748/wjg.v22.i43.9571]

17 John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001; 34: 889-895 [PMID: 11679959 DOI: 10.1053/jhep.2001.29134]

18 Gray M, Singh S, Zucker SD. Influence of Type 2 Diabetes Mellitus and Preoperative Hemoglobin A1c Levels on Outcomes of Liver Transplantation. Hepatobiliary Pancreat Commun 2019; 3: 574-586 [PMID: 30976746 DOI: 10.1002/hepc.13231]

19 Younossi ZM, Golabi P, de Avalia L, Paik JM, Srishord M, Fukui N, Qu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71: 79-801 [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021]

20 Targher G, Day CP, Bono E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]

21 Yuan H, Tuttle-Newhall JE, Chawa V, Schnitzler MA, Xiao H, Axetelod D, Drezhsbashvili N, Lentine KL. Prognostic impact of mechanical ventilation after liver transplantation: a national database study. J Am Surg 2014; 208: 582-590 [PMID: 25151187 DOI: 10.1016/j.amjsurg.2014.06.004]

22 Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 2012; 18: 1290-1301 [PMID: 22847917 DOI: 10.1002/lt.23522]
